Crosstalk between tumor cells and lymphocytes modulates heparanase expression

Heparanase (HPSE) is an endo-beta-glucuronidase that degrades heparan sulfate (HS) chains on proteoglycans. The oligosaccharides generated by HPSE promote angiogenesis, tumor growth and metastasis. Heparanase-2 (HPSE2), a close homolog of HPSE, does not exhibit catalytic activity. Previous studies h...

Full description

Saved in:
Bibliographic Details
Published inJournal of translational medicine Vol. 17; no. 1; pp. 103 - 14
Main Authors Theodoro, Thérèse Rachell, Matos, Leandro Luongo, Cavalheiro, Renan Pelluzzi, Justo, Giselle Zenker, Nader, Helena Bonciani, Pinhal, Maria Aparecida Silva
Format Journal Article
LanguageEnglish
Published England BioMed Central Ltd 29.03.2019
BioMed Central
BMC
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Heparanase (HPSE) is an endo-beta-glucuronidase that degrades heparan sulfate (HS) chains on proteoglycans. The oligosaccharides generated by HPSE promote angiogenesis, tumor growth and metastasis. Heparanase-2 (HPSE2), a close homolog of HPSE, does not exhibit catalytic activity. Previous studies have demonstrated that serum or plasma from breast cancer patients showed increased expression of both heparanases in circulating lymphocytes. The aim of this study was to better understand the mechanisms involved in the upregulation of heparanases in circulating lymphocytes. Lymphocytes collected from healthy women were incubated in the presence of MCF-7 breast cancer cells (co-culture) to stimulate HPSE and HPSE2 overexpression. The protein level of heparanases was evaluated by immunocytochemistry, while mRNA expression was determined by quantitative RT-PCR. The medium obtained from co-culture of MCF-7 cells and circulating lymphocytes stimulated the expression of HPSE and HPSE2. Previous treatment of the co-culture medium with an anti-heparan sulfate proteoglycan antibody or heparitinase II inhibited the upregulation of heparanases in circulating lymphocytes. The addition of exogenous heparan sulfate (HS) enhanced the expression of both heparanases. Moreover, the co-cultured cells, as well as MCF-7 cells, secreted a higher number of exosomes expressing an increased level of HS compared to that of the exosomes secreted by circulating lymphocytes from women who were not affected by cancer. The results revealed that HS is likely responsible for mediating the expression of heparanases in circulating lymphocytes. HS secreted by tumor cells might be carried by exosome particles, confirming the key role of tumor cells, as well as secreted HS, in upregulating the expression of heparanases, suggesting a possible mechanism of crosstalk between tumor cells and circulating lymphocytes.
AbstractList Background Heparanase (HPSE) is an endo-beta-glucuronidase that degrades heparan sulfate (HS) chains on proteoglycans. The oligosaccharides generated by HPSE promote angiogenesis, tumor growth and metastasis. Heparanase-2 (HPSE2), a close homolog of HPSE, does not exhibit catalytic activity. Previous studies have demonstrated that serum or plasma from breast cancer patients showed increased expression of both heparanases in circulating lymphocytes. The aim of this study was to better understand the mechanisms involved in the upregulation of heparanases in circulating lymphocytes. Methods Lymphocytes collected from healthy women were incubated in the presence of MCF-7 breast cancer cells (co-culture) to stimulate HPSE and HPSE2 overexpression. The protein level of heparanases was evaluated by immunocytochemistry, while mRNA expression was determined by quantitative RT-PCR. Results The medium obtained from co-culture of MCF-7 cells and circulating lymphocytes stimulated the expression of HPSE and HPSE2. Previous treatment of the co-culture medium with an anti-heparan sulfate proteoglycan antibody or heparitinase II inhibited the upregulation of heparanases in circulating lymphocytes. The addition of exogenous heparan sulfate (HS) enhanced the expression of both heparanases. Moreover, the co-cultured cells, as well as MCF-7 cells, secreted a higher number of exosomes expressing an increased level of HS compared to that of the exosomes secreted by circulating lymphocytes from women who were not affected by cancer. Conclusions The results revealed that HS is likely responsible for mediating the expression of heparanases in circulating lymphocytes. HS secreted by tumor cells might be carried by exosome particles, confirming the key role of tumor cells, as well as secreted HS, in upregulating the expression of heparanases, suggesting a possible mechanism of crosstalk between tumor cells and circulating lymphocytes. Keywords: Tumor microenvironment, Breast neoplasms, HPSE, HPSE2, Heparan sulfate, Proteoglycans
Heparanase (HPSE) is an endo-beta-glucuronidase that degrades heparan sulfate (HS) chains on proteoglycans. The oligosaccharides generated by HPSE promote angiogenesis, tumor growth and metastasis. Heparanase-2 (HPSE2), a close homolog of HPSE, does not exhibit catalytic activity. Previous studies have demonstrated that serum or plasma from breast cancer patients showed increased expression of both heparanases in circulating lymphocytes. The aim of this study was to better understand the mechanisms involved in the upregulation of heparanases in circulating lymphocytes.BACKGROUNDHeparanase (HPSE) is an endo-beta-glucuronidase that degrades heparan sulfate (HS) chains on proteoglycans. The oligosaccharides generated by HPSE promote angiogenesis, tumor growth and metastasis. Heparanase-2 (HPSE2), a close homolog of HPSE, does not exhibit catalytic activity. Previous studies have demonstrated that serum or plasma from breast cancer patients showed increased expression of both heparanases in circulating lymphocytes. The aim of this study was to better understand the mechanisms involved in the upregulation of heparanases in circulating lymphocytes.Lymphocytes collected from healthy women were incubated in the presence of MCF-7 breast cancer cells (co-culture) to stimulate HPSE and HPSE2 overexpression. The protein level of heparanases was evaluated by immunocytochemistry, while mRNA expression was determined by quantitative RT-PCR.METHODSLymphocytes collected from healthy women were incubated in the presence of MCF-7 breast cancer cells (co-culture) to stimulate HPSE and HPSE2 overexpression. The protein level of heparanases was evaluated by immunocytochemistry, while mRNA expression was determined by quantitative RT-PCR.The medium obtained from co-culture of MCF-7 cells and circulating lymphocytes stimulated the expression of HPSE and HPSE2. Previous treatment of the co-culture medium with an anti-heparan sulfate proteoglycan antibody or heparitinase II inhibited the upregulation of heparanases in circulating lymphocytes. The addition of exogenous heparan sulfate (HS) enhanced the expression of both heparanases. Moreover, the co-cultured cells, as well as MCF-7 cells, secreted a higher number of exosomes expressing an increased level of HS compared to that of the exosomes secreted by circulating lymphocytes from women who were not affected by cancer.RESULTSThe medium obtained from co-culture of MCF-7 cells and circulating lymphocytes stimulated the expression of HPSE and HPSE2. Previous treatment of the co-culture medium with an anti-heparan sulfate proteoglycan antibody or heparitinase II inhibited the upregulation of heparanases in circulating lymphocytes. The addition of exogenous heparan sulfate (HS) enhanced the expression of both heparanases. Moreover, the co-cultured cells, as well as MCF-7 cells, secreted a higher number of exosomes expressing an increased level of HS compared to that of the exosomes secreted by circulating lymphocytes from women who were not affected by cancer.The results revealed that HS is likely responsible for mediating the expression of heparanases in circulating lymphocytes. HS secreted by tumor cells might be carried by exosome particles, confirming the key role of tumor cells, as well as secreted HS, in upregulating the expression of heparanases, suggesting a possible mechanism of crosstalk between tumor cells and circulating lymphocytes.CONCLUSIONSThe results revealed that HS is likely responsible for mediating the expression of heparanases in circulating lymphocytes. HS secreted by tumor cells might be carried by exosome particles, confirming the key role of tumor cells, as well as secreted HS, in upregulating the expression of heparanases, suggesting a possible mechanism of crosstalk between tumor cells and circulating lymphocytes.
Abstract Background Heparanase (HPSE) is an endo-beta-glucuronidase that degrades heparan sulfate (HS) chains on proteoglycans. The oligosaccharides generated by HPSE promote angiogenesis, tumor growth and metastasis. Heparanase-2 (HPSE2), a close homolog of HPSE, does not exhibit catalytic activity. Previous studies have demonstrated that serum or plasma from breast cancer patients showed increased expression of both heparanases in circulating lymphocytes. The aim of this study was to better understand the mechanisms involved in the upregulation of heparanases in circulating lymphocytes. Methods Lymphocytes collected from healthy women were incubated in the presence of MCF-7 breast cancer cells (co-culture) to stimulate HPSE and HPSE2 overexpression. The protein level of heparanases was evaluated by immunocytochemistry, while mRNA expression was determined by quantitative RT-PCR. Results The medium obtained from co-culture of MCF-7 cells and circulating lymphocytes stimulated the expression of HPSE and HPSE2. Previous treatment of the co-culture medium with an anti-heparan sulfate proteoglycan antibody or heparitinase II inhibited the upregulation of heparanases in circulating lymphocytes. The addition of exogenous heparan sulfate (HS) enhanced the expression of both heparanases. Moreover, the co-cultured cells, as well as MCF-7 cells, secreted a higher number of exosomes expressing an increased level of HS compared to that of the exosomes secreted by circulating lymphocytes from women who were not affected by cancer. Conclusions The results revealed that HS is likely responsible for mediating the expression of heparanases in circulating lymphocytes. HS secreted by tumor cells might be carried by exosome particles, confirming the key role of tumor cells, as well as secreted HS, in upregulating the expression of heparanases, suggesting a possible mechanism of crosstalk between tumor cells and circulating lymphocytes.
Heparanase (HPSE) is an endo-beta-glucuronidase that degrades heparan sulfate (HS) chains on proteoglycans. The oligosaccharides generated by HPSE promote angiogenesis, tumor growth and metastasis. Heparanase-2 (HPSE2), a close homolog of HPSE, does not exhibit catalytic activity. Previous studies have demonstrated that serum or plasma from breast cancer patients showed increased expression of both heparanases in circulating lymphocytes. The aim of this study was to better understand the mechanisms involved in the upregulation of heparanases in circulating lymphocytes. Lymphocytes collected from healthy women were incubated in the presence of MCF-7 breast cancer cells (co-culture) to stimulate HPSE and HPSE2 overexpression. The protein level of heparanases was evaluated by immunocytochemistry, while mRNA expression was determined by quantitative RT-PCR. The medium obtained from co-culture of MCF-7 cells and circulating lymphocytes stimulated the expression of HPSE and HPSE2. Previous treatment of the co-culture medium with an anti-heparan sulfate proteoglycan antibody or heparitinase II inhibited the upregulation of heparanases in circulating lymphocytes. The addition of exogenous heparan sulfate (HS) enhanced the expression of both heparanases. Moreover, the co-cultured cells, as well as MCF-7 cells, secreted a higher number of exosomes expressing an increased level of HS compared to that of the exosomes secreted by circulating lymphocytes from women who were not affected by cancer. The results revealed that HS is likely responsible for mediating the expression of heparanases in circulating lymphocytes. HS secreted by tumor cells might be carried by exosome particles, confirming the key role of tumor cells, as well as secreted HS, in upregulating the expression of heparanases, suggesting a possible mechanism of crosstalk between tumor cells and circulating lymphocytes.
Background Heparanase (HPSE) is an endo-beta-glucuronidase that degrades heparan sulfate (HS) chains on proteoglycans. The oligosaccharides generated by HPSE promote angiogenesis, tumor growth and metastasis. Heparanase-2 (HPSE2), a close homolog of HPSE, does not exhibit catalytic activity. Previous studies have demonstrated that serum or plasma from breast cancer patients showed increased expression of both heparanases in circulating lymphocytes. The aim of this study was to better understand the mechanisms involved in the upregulation of heparanases in circulating lymphocytes. Methods Lymphocytes collected from healthy women were incubated in the presence of MCF-7 breast cancer cells (co-culture) to stimulate HPSE and HPSE2 overexpression. The protein level of heparanases was evaluated by immunocytochemistry, while mRNA expression was determined by quantitative RT-PCR. Results The medium obtained from co-culture of MCF-7 cells and circulating lymphocytes stimulated the expression of HPSE and HPSE2. Previous treatment of the co-culture medium with an anti-heparan sulfate proteoglycan antibody or heparitinase II inhibited the upregulation of heparanases in circulating lymphocytes. The addition of exogenous heparan sulfate (HS) enhanced the expression of both heparanases. Moreover, the co-cultured cells, as well as MCF-7 cells, secreted a higher number of exosomes expressing an increased level of HS compared to that of the exosomes secreted by circulating lymphocytes from women who were not affected by cancer. Conclusions The results revealed that HS is likely responsible for mediating the expression of heparanases in circulating lymphocytes. HS secreted by tumor cells might be carried by exosome particles, confirming the key role of tumor cells, as well as secreted HS, in upregulating the expression of heparanases, suggesting a possible mechanism of crosstalk between tumor cells and circulating lymphocytes.
Heparanase (HPSE) is an endo-beta-glucuronidase that degrades heparan sulfate (HS) chains on proteoglycans. The oligosaccharides generated by HPSE promote angiogenesis, tumor growth and metastasis. Heparanase-2 (HPSE2), a close homolog of HPSE, does not exhibit catalytic activity. Previous studies have demonstrated that serum or plasma from breast cancer patients showed increased expression of both heparanases in circulating lymphocytes. The aim of this study was to better understand the mechanisms involved in the upregulation of heparanases in circulating lymphocytes. Lymphocytes collected from healthy women were incubated in the presence of MCF-7 breast cancer cells (co-culture) to stimulate HPSE and HPSE2 overexpression. The protein level of heparanases was evaluated by immunocytochemistry, while mRNA expression was determined by quantitative RT-PCR. The medium obtained from co-culture of MCF-7 cells and circulating lymphocytes stimulated the expression of HPSE and HPSE2. Previous treatment of the co-culture medium with an anti-heparan sulfate proteoglycan antibody or heparitinase II inhibited the upregulation of heparanases in circulating lymphocytes. The addition of exogenous heparan sulfate (HS) enhanced the expression of both heparanases. Moreover, the co-cultured cells, as well as MCF-7 cells, secreted a higher number of exosomes expressing an increased level of HS compared to that of the exosomes secreted by circulating lymphocytes from women who were not affected by cancer. The results revealed that HS is likely responsible for mediating the expression of heparanases in circulating lymphocytes. HS secreted by tumor cells might be carried by exosome particles, confirming the key role of tumor cells, as well as secreted HS, in upregulating the expression of heparanases, suggesting a possible mechanism of crosstalk between tumor cells and circulating lymphocytes.
ArticleNumber 103
Audience Academic
Author Theodoro, Thérèse Rachell
Justo, Giselle Zenker
Matos, Leandro Luongo
Pinhal, Maria Aparecida Silva
Cavalheiro, Renan Pelluzzi
Nader, Helena Bonciani
Author_xml – sequence: 1
  givenname: Thérèse Rachell
  surname: Theodoro
  fullname: Theodoro, Thérèse Rachell
– sequence: 2
  givenname: Leandro Luongo
  surname: Matos
  fullname: Matos, Leandro Luongo
– sequence: 3
  givenname: Renan Pelluzzi
  surname: Cavalheiro
  fullname: Cavalheiro, Renan Pelluzzi
– sequence: 4
  givenname: Giselle Zenker
  surname: Justo
  fullname: Justo, Giselle Zenker
– sequence: 5
  givenname: Helena Bonciani
  surname: Nader
  fullname: Nader, Helena Bonciani
– sequence: 6
  givenname: Maria Aparecida Silva
  surname: Pinhal
  fullname: Pinhal, Maria Aparecida Silva
BackLink https://www.ncbi.nlm.nih.gov/pubmed/30922347$$D View this record in MEDLINE/PubMed
BookMark eNp9Ustu1DAUjVARfcAHsEGR2LBJ8dvxBqka8ahUxAbWlmPfzHhI7MFOgPbrcZhSOhVCXtyr63POfeicVkchBqiq5xidY9yK1xkTJWSDsGpwy2lz86g6wUyqhrdSHN3Lj6vTnLcIEcaZelIdU6QIoUyeVB9XKeY8meFr3cH0AyDU0zzGVFsYhlyb4Orhetxtor2eINdjdPNglmwDO5NMMBlq-LlLkLOP4Wn1uDdDhme38az68u7t59WH5urT-8vVxVVjuUBTY1lvesopVx2THeCeO0YpcDDGIIQFEr1UAmGJTQkOqLOt7J0hDknRG0TPqsu9rotmq3fJjyZd62i8_l2Iaa1NmrwdQBPMOEadItJhBn1pISUhnCDbKSuwLVpv9lq7uRvBWQhTMsOB6OFP8Bu9jt-1YFQpJYrAq1uBFL_NkCc9-ryczwSIc9aEICRbLuky98sH0G2cUyinKiiMWcuFav-i1qYs4EMfS1-7iOoL3mJKVcsX1Pk_UOU5GL0tRul9qR8QXtxf9G7DP2YoALwH2MUTCfo7CEZ6MZzeG04Xw-nFcPqmcOQDjvWTmYoXyjR--A_zF1ms2hU
CitedBy_id crossref_primary_10_3390_cancers13061441
crossref_primary_10_1016_j_semcancer_2019_07_014
crossref_primary_10_3390_cancers13194798
crossref_primary_10_1016_j_oraloncology_2020_104909
crossref_primary_10_3390_biomedicines12061190
crossref_primary_10_1080_14712598_2020_1813276
crossref_primary_10_4103_jcrt_jcrt_1072_22
crossref_primary_10_1038_s41419_021_03825_2
crossref_primary_10_1186_s12967_020_02624_1
crossref_primary_10_3390_molecules25020390
crossref_primary_10_3390_ijms21207802
Cites_doi 10.1080/03008200802143281
10.1111/febs.12168
10.1186/s13058-018-0995-x
10.1002/jcb.20602
10.1593/neo.07241
10.3389/fonc.2013.00231
10.18632/oncotarget.16575
10.1006/bbrc.2000.3586
10.1001/jamaoncol.2017.2140
10.1074/jbc.M111.330803
10.1080/23723556.2015.1047556
10.1016/j.tibs.2017.10.007
10.1172/JCI45817
10.1186/1471-2407-13-444
10.1016/0304-4165(87)90016-X
10.1038/cmi.2011.47
10.1007/s00281-018-0689-6
10.1074/jbc.C112.444562
10.1007/s10549-018-5043-0
10.1590/S1807-59322006000500008
10.1371/journal.pone.0204513
10.1016/j.cell.2011.02.013
10.1016/S0021-9258(17)44833-2
10.1038/nrc2618
10.1038/s41388-018-0128-0
10.1074/jbc.M611259200
10.3390/cells7100167
10.1093/neuonc/nov170
10.1038/cr.2015.29
10.1007/978-3-319-95294-9_4
10.1016/j.matbio.2017.09.001
10.1073/pnas.1304266110
10.1016/j.exphem.2016.08.006
10.1016/0304-4165(74)90237-2
10.1016/j.bbrc.2017.02.060
10.1038/ncb2502
10.1371/journal.pone.0010135
10.1186/s12943-014-0279-8
10.1111/febs.12111
ContentType Journal Article
Copyright COPYRIGHT 2019 BioMed Central Ltd.
2019. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
The Author(s) 2019
Copyright_xml – notice: COPYRIGHT 2019 BioMed Central Ltd.
– notice: 2019. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
– notice: The Author(s) 2019
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
3V.
7T5
7X7
7XB
88E
8FI
8FJ
8FK
ABUWG
AFKRA
AZQEC
BENPR
CCPQU
DWQXO
FYUFA
GHDGH
H94
K9.
M0S
M1P
PHGZM
PHGZT
PIMPY
PJZUB
PKEHL
PPXIY
PQEST
PQQKQ
PQUKI
PRINS
7X8
5PM
DOA
DOI 10.1186/s12967-019-1853-z
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
ProQuest Central (Corporate)
Immunology Abstracts
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central Essentials
ProQuest Central
ProQuest One Community College
ProQuest Central
Health Research Premium Collection
Health Research Premium Collection (Alumni)
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
ProQuest Health & Medical Collection
Medical Database
ProQuest Central Premium
ProQuest One Academic
Publicly Available Content Database
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
Publicly Available Content Database
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Central China
ProQuest Central
ProQuest Health & Medical Research Collection
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
ProQuest Central Korea
Health & Medical Research Collection
AIDS and Cancer Research Abstracts
ProQuest Central (New)
ProQuest Medical Library (Alumni)
ProQuest One Academic Eastern Edition
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
ProQuest Hospital Collection (Alumni)
ProQuest Health & Medical Complete
ProQuest Medical Library
ProQuest One Academic UKI Edition
Immunology Abstracts
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList
MEDLINE - Academic


Publicly Available Content Database
MEDLINE
Database_xml – sequence: 1
  dbid: DOA
  name: Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 4
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1479-5876
EndPage 14
ExternalDocumentID oai_doaj_org_article_214510b927d14efeaa7722520cb9c61c
PMC6439996
A581339858
30922347
10_1186_s12967_019_1853_z
Genre Research Support, Non-U.S. Gov't
Journal Article
GeographicLocations California
GeographicLocations_xml – name: California
GrantInformation_xml – fundername: ;
  grantid: 2016/01357-8
GroupedDBID ---
0R~
29L
2WC
53G
5VS
6PF
7X7
88E
8FI
8FJ
AAFWJ
AAJSJ
AASML
AAWTL
AAYXX
ABDBF
ABUWG
ACGFO
ACGFS
ACIHN
ACIWK
ACPRK
ACUHS
ADBBV
ADUKV
AEAQA
AENEX
AFKRA
AFPKN
AFRAH
AHBYD
AHMBA
AHYZX
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AMKLP
AMTXH
AOIJS
BAPOH
BAWUL
BCNDV
BENPR
BFQNJ
BMC
BPHCQ
BVXVI
C6C
CCPQU
CITATION
CS3
DIK
DU5
E3Z
EBD
EBLON
EBS
EJD
ESX
F5P
FYUFA
GROUPED_DOAJ
GX1
H13
HMCUK
HYE
IAO
IHR
INH
INR
ITC
KQ8
M1P
M48
M~E
O5R
O5S
OK1
OVT
P2P
PGMZT
PHGZM
PHGZT
PIMPY
PQQKQ
PROAC
PSQYO
RBZ
RNS
ROL
RPM
RSV
SBL
SOJ
TR2
TUS
UKHRP
WOQ
WOW
XSB
~8M
CGR
CUY
CVF
ECM
EIF
NPM
PMFND
3V.
7T5
7XB
8FK
AZQEC
DWQXO
H94
K9.
PJZUB
PKEHL
PPXIY
PQEST
PQUKI
PRINS
7X8
5PM
PUEGO
ID FETCH-LOGICAL-c560t-c4faf35359b47be1f5d433e5eaaa001606f7960171a960de3dc87fda2d076fa03
IEDL.DBID M48
ISSN 1479-5876
IngestDate Wed Aug 27 01:23:40 EDT 2025
Thu Aug 21 18:38:33 EDT 2025
Fri Jul 11 07:08:11 EDT 2025
Fri Jul 25 19:55:21 EDT 2025
Tue Jun 17 21:07:30 EDT 2025
Tue Jun 10 20:20:03 EDT 2025
Thu Apr 03 06:59:03 EDT 2025
Tue Jul 01 03:51:11 EDT 2025
Thu Apr 24 23:12:32 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Keywords Heparan sulfate
Breast neoplasms
Proteoglycans
HPSE
HPSE2
Tumor microenvironment
Language English
License Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c560t-c4faf35359b47be1f5d433e5eaaa001606f7960171a960de3dc87fda2d076fa03
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
OpenAccessLink https://www.proquest.com/docview/2211485698?pq-origsite=%requestingapplication%
PMID 30922347
PQID 2211485698
PQPubID 43076
PageCount 14
ParticipantIDs doaj_primary_oai_doaj_org_article_214510b927d14efeaa7722520cb9c61c
pubmedcentral_primary_oai_pubmedcentral_nih_gov_6439996
proquest_miscellaneous_2200785730
proquest_journals_2211485698
gale_infotracmisc_A581339858
gale_infotracacademiconefile_A581339858
pubmed_primary_30922347
crossref_primary_10_1186_s12967_019_1853_z
crossref_citationtrail_10_1186_s12967_019_1853_z
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2019-03-29
PublicationDateYYYYMMDD 2019-03-29
PublicationDate_xml – month: 03
  year: 2019
  text: 2019-03-29
  day: 29
PublicationDecade 2010
PublicationPlace England
PublicationPlace_xml – name: England
– name: London
PublicationTitle Journal of translational medicine
PublicationTitleAlternate J Transl Med
PublicationYear 2019
Publisher BioMed Central Ltd
BioMed Central
BMC
Publisher_xml – name: BioMed Central Ltd
– name: BioMed Central
– name: BMC
References D Hanahan (1853_CR11) 2011; 144
Z Wan (1853_CR19) 2018; 8
I Vlodavsky (1853_CR40) 2018; 43
T Shtam (1853_CR20) 2018
CA Thompson (1853_CR27) 2013; 288
LL Matos (1853_CR33) 2006; 61
HB Nader (1853_CR35) 1990; 265
HC Lim (1853_CR39) 2015; 14
M Bellone (1853_CR16) 2013; 3
AK Simi (1853_CR1) 2018; 1092
G David (1853_CR30) 2015; 3
VC Ramani (1853_CR10) 2013; 280
B Roucourt (1853_CR29) 2015; 25
Y Yang (1853_CR8) 2007; 282
K Harano (1853_CR14) 2018; 13
ER Suarez (1853_CR37) 2013; 13
YM Michelacci (1853_CR34) 1987; 923
M Bitan (1853_CR17) 2010; 5
M Nawaz (1853_CR24) 2018; 7
MF Baietti (1853_CR26) 2012; 14
E Zhao (1853_CR12) 2012; 9
RD Sanderson (1853_CR3) 2005; 96
CP Dietrich (1853_CR32) 1974; 345
TR Theodoro (1853_CR18) 2007; 9
C Chute (1853_CR2) 2018; 20
JA Joyce (1853_CR21) 2009; 9
HC Christianson (1853_CR28) 2013; 110
I Vlodavsky (1853_CR4) 2008; 49
S Yu (1853_CR7) 2017; 485
T Karn (1853_CR13) 2017; 3
MW Graner (1853_CR22) 2018; 40
W Jiao (1853_CR5) 2018; 37
JE Hellwinkel (1853_CR23) 2015; 18
B Heyman (1853_CR31) 2016; 44
H Hassan (1853_CR38) 2013; 280
SK Bandari (1853_CR9) 2018; 65
H Salmon (1853_CR15) 2012; 122
VC Ramani (1853_CR25) 2012; 287
X Sun (1853_CR36) 2017; 8
E McKenzie (1853_CR6) 2000; 3
References_xml – volume: 49
  start-page: 207
  year: 2008
  ident: 1853_CR4
  publication-title: Connect Tissue Res
  doi: 10.1080/03008200802143281
– volume: 280
  start-page: 2294
  year: 2013
  ident: 1853_CR10
  publication-title: FEBS J
  doi: 10.1111/febs.12168
– volume: 20
  start-page: 66
  year: 2018
  ident: 1853_CR2
  publication-title: Breast Cancer Res
  doi: 10.1186/s13058-018-0995-x
– volume: 96
  start-page: 897
  year: 2005
  ident: 1853_CR3
  publication-title: J Cell Biochem
  doi: 10.1002/jcb.20602
– volume: 9
  start-page: 504
  year: 2007
  ident: 1853_CR18
  publication-title: Neoplasia.
  doi: 10.1593/neo.07241
– volume: 3
  start-page: 231
  year: 2013
  ident: 1853_CR16
  publication-title: Front Oncol.
  doi: 10.3389/fonc.2013.00231
– volume: 8
  start-page: 43521
  year: 2017
  ident: 1853_CR36
  publication-title: Oncotarget.
  doi: 10.18632/oncotarget.16575
– volume: 3
  start-page: 1170
  year: 2000
  ident: 1853_CR6
  publication-title: Biochem Biophys Res Commun
  doi: 10.1006/bbrc.2000.3586
– volume: 3
  start-page: 1707
  year: 2017
  ident: 1853_CR13
  publication-title: JAMA Oncol.
  doi: 10.1001/jamaoncol.2017.2140
– volume: 287
  start-page: 9952
  year: 2012
  ident: 1853_CR25
  publication-title: J Biol Chem
  doi: 10.1074/jbc.M111.330803
– volume: 3
  start-page: e1047556
  year: 2015
  ident: 1853_CR30
  publication-title: Mol Cell Oncol.
  doi: 10.1080/23723556.2015.1047556
– volume: 43
  start-page: 18
  year: 2018
  ident: 1853_CR40
  publication-title: Trends Biochem Sci
  doi: 10.1016/j.tibs.2017.10.007
– volume: 122
  start-page: 899
  year: 2012
  ident: 1853_CR15
  publication-title: J Clin Invest.
  doi: 10.1172/JCI45817
– volume: 13
  start-page: 444
  year: 2013
  ident: 1853_CR37
  publication-title: BMC Cancer.
  doi: 10.1186/1471-2407-13-444
– volume: 923
  start-page: 291
  year: 1987
  ident: 1853_CR34
  publication-title: Biochim Biophys Acta
  doi: 10.1016/0304-4165(87)90016-X
– volume: 9
  start-page: 11
  year: 2012
  ident: 1853_CR12
  publication-title: Cell Mol Immunol
  doi: 10.1038/cmi.2011.47
– volume: 40
  start-page: 505
  year: 2018
  ident: 1853_CR22
  publication-title: Semin Immunopathol.
  doi: 10.1007/s00281-018-0689-6
– volume: 288
  start-page: 10093
  year: 2013
  ident: 1853_CR27
  publication-title: J Biol Chem
  doi: 10.1074/jbc.C112.444562
– year: 2018
  ident: 1853_CR20
  publication-title: Breast Cancer Res Treat.
  doi: 10.1007/s10549-018-5043-0
– volume: 61
  start-page: 417
  year: 2006
  ident: 1853_CR33
  publication-title: Clinics.
  doi: 10.1590/S1807-59322006000500008
– volume: 13
  start-page: e0204513
  year: 2018
  ident: 1853_CR14
  publication-title: PLoS ONE
  doi: 10.1371/journal.pone.0204513
– volume: 8
  start-page: 1661
  year: 2018
  ident: 1853_CR19
  publication-title: Am J Cancer Res.
– volume: 144
  start-page: 646
  year: 2011
  ident: 1853_CR11
  publication-title: Cell
  doi: 10.1016/j.cell.2011.02.013
– volume: 265
  start-page: 16807
  year: 1990
  ident: 1853_CR35
  publication-title: J Biol Chem
  doi: 10.1016/S0021-9258(17)44833-2
– volume: 9
  start-page: 239
  year: 2009
  ident: 1853_CR21
  publication-title: Nat Rev Cancer
  doi: 10.1038/nrc2618
– volume: 37
  start-page: 2728
  year: 2018
  ident: 1853_CR5
  publication-title: Oncogene
  doi: 10.1038/s41388-018-0128-0
– volume: 282
  start-page: 13326
  year: 2007
  ident: 1853_CR8
  publication-title: J Biol Chem
  doi: 10.1074/jbc.M611259200
– volume: 7
  start-page: E167
  issue: 10
  year: 2018
  ident: 1853_CR24
  publication-title: Cells.
  doi: 10.3390/cells7100167
– volume: 18
  start-page: 497
  year: 2015
  ident: 1853_CR23
  publication-title: Neuro-Oncology.
  doi: 10.1093/neuonc/nov170
– volume: 25
  start-page: 412
  year: 2015
  ident: 1853_CR29
  publication-title: Cell Res
  doi: 10.1038/cr.2015.29
– volume: 1092
  start-page: 57
  year: 2018
  ident: 1853_CR1
  publication-title: Adv Exp Med Biol
  doi: 10.1007/978-3-319-95294-9_4
– volume: 65
  start-page: 104
  year: 2018
  ident: 1853_CR9
  publication-title: Matrix Biol
  doi: 10.1016/j.matbio.2017.09.001
– volume: 110
  start-page: 17380
  year: 2013
  ident: 1853_CR28
  publication-title: PNAS
  doi: 10.1073/pnas.1304266110
– volume: 44
  start-page: 1002
  year: 2016
  ident: 1853_CR31
  publication-title: Exp Hematol
  doi: 10.1016/j.exphem.2016.08.006
– volume: 345
  start-page: 34
  year: 1974
  ident: 1853_CR32
  publication-title: Biochim Biophys Acta
  doi: 10.1016/0304-4165(74)90237-2
– volume: 485
  start-page: 432
  year: 2017
  ident: 1853_CR7
  publication-title: Biochem Biophys Res Commun
  doi: 10.1016/j.bbrc.2017.02.060
– volume: 14
  start-page: 677
  year: 2012
  ident: 1853_CR26
  publication-title: Nat Cell Biol
  doi: 10.1038/ncb2502
– volume: 5
  start-page: e10135
  year: 2010
  ident: 1853_CR17
  publication-title: PLoS ONE
  doi: 10.1371/journal.pone.0010135
– volume: 14
  start-page: 15
  year: 2015
  ident: 1853_CR39
  publication-title: Mol Cancer.
  doi: 10.1186/s12943-014-0279-8
– volume: 280
  start-page: 2216
  year: 2013
  ident: 1853_CR38
  publication-title: FEBS J
  doi: 10.1111/febs.12111
SSID ssj0024549
Score 2.3020513
Snippet Heparanase (HPSE) is an endo-beta-glucuronidase that degrades heparan sulfate (HS) chains on proteoglycans. The oligosaccharides generated by HPSE promote...
Background Heparanase (HPSE) is an endo-beta-glucuronidase that degrades heparan sulfate (HS) chains on proteoglycans. The oligosaccharides generated by HPSE...
Abstract Background Heparanase (HPSE) is an endo-beta-glucuronidase that degrades heparan sulfate (HS) chains on proteoglycans. The oligosaccharides generated...
SourceID doaj
pubmedcentral
proquest
gale
pubmed
crossref
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
StartPage 103
SubjectTerms Angiogenesis
Antibodies
Biosynthesis
Bone marrow
Breast cancer
Breast neoplasms
Breast Neoplasms - genetics
Breast Neoplasms - metabolism
Breast Neoplasms - pathology
Cancer cells
Cancer metastasis
Cancer therapies
Cell adhesion & migration
Cell Communication - drug effects
Cell Communication - physiology
Cell culture
Cell growth
Cells, Cultured
Coculture Techniques
Culture Media, Conditioned - pharmacology
Exosomes
Extracellular matrix
Female
Gene expression
Gene Expression Regulation, Enzymologic - drug effects
Gene Expression Regulation, Neoplastic - drug effects
Glucuronidase - genetics
Glucuronidase - metabolism
Growth factors
Health aspects
Heparan sulfate
Heparitin Sulfate - metabolism
Heparitin Sulfate - physiology
HPSE
HPSE2
Humans
Immunocytochemistry
Lymphocyte Activation - genetics
Lymphocytes
Lymphocytes - metabolism
Lymphocytes - physiology
MCF-7 Cells
Messenger RNA
Metastases
Metastasis
Oligosaccharides
Polymerase chain reaction
Proteoglycans
Receptor Cross-Talk - drug effects
Receptor Cross-Talk - immunology
Risk factors
RNA
Stem cells
Sulfates
Tumor cells
Tumor microenvironment
Tumors
Women's health
SummonAdditionalLinks – databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1ba9RAFB6kD8UX0dZLtMoIgiCEZjK3zGMtllJYnyz0bZgrFdtEurtg--s9J5ldNgj64lNCZkIyZ87lO5uz3yHkg5K-c5mZWmkha8Ed-EEvWC1lSJ0TsXFjm87FV3V-KS6u5NVOqy-sCZvogSfBHSOTNmu8aXVkIuXkHODBVrZN8CYoFtD7QszbJFMblj1Ie8o3TNap4yVENYUllqbG-FQ_zKLQSNb_p0veiUnzesmdAHT2lDwpyJGeTG_8jDxK_QHZX5Rv44dkcYqPAiz9g5biK7pa3w53FH-bX1LXR3pzD3s3hHuAl_R2iNi5C86uE_J_9xDOaPpV6mL75-Ty7Mu30_O6NEuoA4CWVR1EdplLLo0X2ieWZRScJwkCc2MzaZU1ZCtMMweHmHgMnc7RtbHRKruGvyB7_dCnV4TyMRNzLfctmLhy3iSVwRkAVtMesteKNBvh2VCYxLGhxY0dM4pO2UneFuRtUd72oSKftrf8nGg0_jb5M-7IdiIyYI8XQC9s0Qv7L72oyEfcT4t2Ci8XXPm7ASwRGa_siewgPTed7CpyNJsJ9hXmwxuNsMW-l7ZtMY-UysDw--0w3ok1a30a1jgH8ZcEF1qRl5MCbZfEGwO4TOiK6JlqzdY8H-m_X4_s3wghIUl9_T-E9IY8btEoGuznd0T2Vnfr9BZA1sq_G-3pN-AkIsc
  priority: 102
  providerName: Directory of Open Access Journals
– databaseName: Health & Medical Collection
  dbid: 7X7
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1bS9xAFD60Fkpfir0atSWFQqEQTDLXPImVihS2TxX2bZhbaqkmdi-g_nrPyc6uhoJPG3YmJDNzLt-ZOfkOwGcpnLZt1RRScVFwZtEOOl4VQvioLQ-lHcp0Tn7K0zP-YyqmacNtntIq1zZxMNSh97RHflDXhNyFbPTh1b-CqkbR6WoqofEUnhF1GUm1mt4HXByDn3SSWWl5MEffJinRsinISxW3I180UPb_b5gfeKZx1uQDN3SyDS8TfsyPVgv-Cp7E7jU8n6QT8jcwOaZHIaL-m6cUrHyxvOxnOe3Qz3PbhfziBlew9zcIMvPLPlD9Lrw6j8QC3qFTy-N1yo7t3sLZyfdfx6dFKplQeIQui8Lz1rZMMNE4rlysWhE4Y1FEa-1QUlq2CmOWSlUWf0JkwWvVBluHUsnWluwdbHV9F3cgZ0M8ZmvmalR0aV0TZYsmARGbchjDZlCuJ8_4xCdOZS0uzBBXaGlW821wvg3Nt7nN4OvmlqsVmcZjnb_Rimw6Eg_28Ec_-22SWhniWa9K19QqVDy2OEyMFmpRl941XlY-gy-0noa0FV_O2_TRAQ6ReK_MkdAYpDda6Az2Rz1Ry_y4eS0RJmn53NzLZAafNs10J2WudbFfUh9CYQINaQbvVwK0GRIrG0RnXGWgRqI1GvO4pftzPnCAE5DEUHX38dfagxc1iXtJ9fr2YWsxW8YPCKIW7uOgKXc67Rq_
  priority: 102
  providerName: ProQuest
Title Crosstalk between tumor cells and lymphocytes modulates heparanase expression
URI https://www.ncbi.nlm.nih.gov/pubmed/30922347
https://www.proquest.com/docview/2211485698
https://www.proquest.com/docview/2200785730
https://pubmed.ncbi.nlm.nih.gov/PMC6439996
https://doaj.org/article/214510b927d14efeaa7722520cb9c61c
Volume 17
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3ri9NAEB_uAeIX8W30LBEEQYjmsY_kg8j1uOMQeshhofhl2d1sPLGXaB9wvb_eme22XvAQ_NKU7ibpzM7rt5nMALwW3JS6yapESMYTVmi0g4ZlCefWlZrVqfZtOkdn4nTMPk34ZAc27a0CA-e3QjvqJzWeTd9d_Vp9RIX_4BW-FO_n6LMEJVBWCXmf5HoX9tExSWpoMGLln9J73EfDGZNVwtEKhIect16i56Z8Nf-_bfYNp9VPqLzhoU7uw70QWsaHa1l4ADuufQh3RuHh-SMYHdGtkM4fccjOihfLy24W0-b9PNZtHU9XuLidXWH8GV92NbX2wm8XjgqEt-jvYncVEmfbxzA-Of5ydJqEbgqJxahmkVjW6KbgBa8Mk8ZlDa9ZUTjutNa-27RoJMKZTGYaD7UralvKptZ5nUrR6LR4Antt17pnEBcequm8MDnaAKFN5USD1gKDOWkQ3kaQbpinbCg1Th0vpspDjlKoNb8V8lsRv9V1BG-3p_xc19n41-Qhrch2IpXI9j90s28qaJyiEuxZaqpc1hlzDZKJQCLneWpNZUVmI3hD66lItPDPWR3eR0ASqSSWOuQl4veq5GUEB72ZqIC2P7yRCLWRX5XnBDS5qHD41XaYzqSkttZ1S5pDARpHGxvB07UAbUkq0goDNyYjkD3R6tHcH2m_X_jy4BRjIop9_j8cfQF3cxL-lBr7HcDeYrZ0LzHaWpgB7MqJHMD-8Pjs8_nA71kMvF7h5_nw628WHShZ
linkProvider Scholars Portal
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9NAEB6VIgEXxBtDASOBkJCs2vuyfUCoFKqUNj21Um7Ler2miNYueQjSH8VvZMZep7WQeuspUXadeGfn8X3Z8QzAGyWLzFRJHqlUyEhwg36wEEkkpXWZEWVs2jad4wM1OhJfJ3KyBn_7Z2EorbL3ia2jLhtL_5FvMkbIXao8-3j2K6KuUXS62rfQ6NRizy1_I2Wbfdj9jPv7lrGdL4fbo8h3FYgsRvd5ZEVlKi65zAuRFi6pZCk4d9IZY9quy6pKEdYnaWLwpXS8tFlalYaVSPkrE3P83htwEwNvTGQvnVwQPIFky5-cJpnanGEsVZTYmUcUFaPzQexrWwT8HwguRcJhlualsLdzD-56vBpudQp2H9Zc_QBujf2J_EMYb9NPIYL_GfqUr3C-OG2mIZ0IzEJTl-HJEjWmsUsEteFpU1K_MHx37KjqeI1BNHR_fDZu_QiOrkWYj2G9bmr3FELe8j_DeMHQsShT5E5V6IIQIaYFcuYA4l542vr65dRG40S3PCZTupO3Rnlrkrc-D-D96pKzrnjHVZM_0Y6sJlLd7faDZvpdezPWVNc9iYucpWUiXIXLRHbCJIttkVuV2ADe0X5q8g54c9b4hxxwiVRnS2_JLOE8z2QWwMZgJlq1HQ73GqG9V5npCxsI4PVqmK6kTLnaNQuaQ6hPouMO4EmnQKsl8ThHNCjSANKBag3WPBypfxy3NccJuCI1fnb1bb2C26PD8b7e3z3Yew53GKl-TL0CN2B9Pl24Fwjg5sXL1mpC-HbdZvoPiQpX_g
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Crosstalk+between+tumor+cells+and+lymphocytes+modulates+heparanase+expression&rft.jtitle=Journal+of+translational+medicine&rft.au=Theodoro%2C+Th%C3%A9r%C3%A8se+Rachell&rft.au=Matos%2C+Leandro+Luongo&rft.au=Cavalheiro%2C+Renan+Pelluzzi&rft.au=Justo%2C+Giselle+Zenker&rft.date=2019-03-29&rft.issn=1479-5876&rft.eissn=1479-5876&rft.volume=17&rft.issue=1&rft_id=info:doi/10.1186%2Fs12967-019-1853-z&rft.externalDBID=n%2Fa&rft.externalDocID=10_1186_s12967_019_1853_z
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1479-5876&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1479-5876&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1479-5876&client=summon